Germline Genetic Markers for Urinary Bladder Cancer Risk, Prognosis and Treatment Response

• Ploeg M , AbenKK, KiemeneyLA: The present and future burden of urinary bladder cancer in the world.World J. Urol.27(3), 289–293 (2009).
   PubMed Web of Science ®Google Scholar
• Ferlay J , BrayF, PisaniP, ParkinDM: GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No.5.version 2.0., International Agency for Research on Cancer Press, France (2004).
   Google Scholar
• Ploeg M , AbenKK, Hulsbergen-van de KaaCA, SchoenbergMP, WitjesJA, KiemeneyLA: Clinical epidemiology of nonurothelial bladder cancer: analysis of The Netherlands Cancer Registry.J. Urol.183(3), 915–920 (2010).
   PubMed Web of Science ®Google Scholar
• Wu X , RosMM, GuJ, KiemeneyL: Epidemiology and genetic susceptibility to bladder cancer.BJU Int.102(9 Pt B), 1207–1215 (2008).
   PubMed Web of Science ®Google Scholar
• Fletcher O , EastonD, AndersonK, GilhamC, JayM, PetoJ: Lifetime risks of common cancers among retinoblastoma survivors.J. Natl Cancer Inst.96(5), 357–363 (2004).
   PubMedGoogle Scholar
• Kleinerman RA , TuckerMA, TaroneREet al.: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up.J. Clin. Oncol.23(10), 2272–2279 (2005).
   PubMed Web of Science ®Google Scholar
• Marees T , MollAC, ImhofSM, de BoerMR, RingensPJ, van LeeuwenFE: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.J. Natl Cancer Inst.100(24), 1771–1779 (2008).
   PubMedGoogle Scholar
• Quezada E , GrippKW: Costello syndrome and related disorders.Curr. Opin. Pediatr.19(6), 636–644 (2007).
   PubMed Web of Science ®Google Scholar
• Aben KK , WitjesJA, SchoenbergMP, Hulsbergen-van deKC, VerbeekAL, KiemeneyLA: Familial aggregation of urothelial cell carcinoma.Int. J. Cancer98(2), 274–278 (2002).
   PubMed Web of Science ®Google Scholar
• Murta-Nascimento C , SilvermanDT, KogevinasMet al.: Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk?Cancer Epidemiol. Biomarkers Prev.16(8), 1595–1600 (2007).
   PubMed Web of Science ®Google Scholar
• Aben KK , BagliettoL, Baffoe-BonnieAet al.: Segregation analysis of urothelial cell carcinoma.Eur. J. Cancer42(10), 1428–1433 (2006).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA : Hereditary bladder cancer.Scand. J. Urol. Nephrol. Suppl.218, 110–115 (2008).
   Google Scholar
• Sylvester RJ : Natural history, recurrence, and progression in superficial bladder cancer.ScientificWorldJournal6, 2617–2625 (2006).
   PubMedGoogle Scholar
• Babjuk M , OosterlinckW, SylvesterR, KaasinenE, BohleA, Palou-RedortaJ: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.Eur. Urol.54(2), 303–314 (2008).
   PubMed Web of Science ®Google Scholar
• Sylvester RJ , van der MeijdenAP, OosterlinckWet al.: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.Eur. Urol.49(3), 466–465 (2006).
   PubMed Web of Science ®Google Scholar
• Stenzl A , CowanNC, De SantisMet al.: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.Eur. Urol.55(4), 815–825 (2009).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA , ThorlaciusS, SulemPet al.: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer.Nat. Genet.40(11), 1307–1312 (2008).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA , SulemP, BesenbacherSet al.: A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer.Nat. Genet.42(5), 415–419 (2010).
   PubMed Web of Science ®Google Scholar
• Wu X , YeY, KiemeneyLAet al.: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer.Nat. Genet.41(9), 991–995 (2009).
   PubMed Web of Science ®Google Scholar
• Brandau S , SuttmannH: Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.Biomed. Pharmacother.61(6), 299–305 (2007).
   PubMed Web of Science ®Google Scholar
• Saint F , SalomonL, QuintelaRet al.: Do prognostic parameters of remission versus relapse after Bacillus Calmette–Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature.Eur. Urol.43(4), 351–360 (2003).
   PubMed Web of Science ®Google Scholar
• Ott OJ , RodelC, WeissCet al.: Radiochemotherapy for bladder cancer.Clin. Oncol. (R. Coll. Radiol.)21(7), 557–565 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , AlbiolS, SuarezC, AlbanellJ: Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents.Crit. Rev. Oncol. Hematol.69(3), 211–222 (2009).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , ChoueiriTK, FougerayRet al.: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.J. Clin. Oncol.28(11), 1850–1855 (2010).
   PubMed Web of Science ®Google Scholar
• Horikawa Y , GuJ, WuX: Genetic susceptibility to bladder cancer with an emphasis on gene–gene and gene–environmental interactions.Curr. Opin. Urol.18(5), 493–498 (2008).
   PubMed Web of Science ®Google Scholar
• Kiemeney LA , GrotenhuisAJ, VermeulenSH, WuX: Genome-wide association studies in bladder cancer: first results and potential relevance.Curr. Opin. Urol.19(5), 540–546 (2009).
   PubMed Web of Science ®Google Scholar
• Kiltie AE : Common predisposition alleles for moderately common cancers: bladder cancer.Curr. Opin. Genet. Dev.20(3), 218–224 (2010).
   PubMed Web of Science ®Google Scholar
• Malats N : Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression.Scand. J. Urol. Nephrol. Suppl.218, 131–140 (2008).
   Google Scholar
• Wu X , LinX, DinneyCP, GuJ, GrossmanHB: Genetic polymorphism in bladder cancer.Front. Biosci.12, 192–213 (2007).
   PubMed Web of Science ®Google Scholar
• Wu X , HildebrandtMA, ChangDW: Genome-wide association studies of bladder cancer risk: a field synopsis of progress and potential applications.Cancer Metastasis Rev.28(3–4), 269–280 (2009).
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M , MalatsN, SilvermanDet al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.Lancet366(9486), 649–659 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M , MalatsN, RealFXet al.: Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk.PLoS. Genet.3(2), E29 (2007).
   PubMed Web of Science ®Google Scholar
• Stern MC , LinJ, FigueroaJDet al.: Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer.Cancer Res.69(17), 6857–6864 (2009).
   PubMed Web of Science ®Google Scholar
• The International HapMap Consortium: A haplotype map of the human genome. Nature 437(7063), 1299–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Frazer KA , BallingerDG, CoxDRet al.: A second generation human haplotype map of over 3.1 million SNPs.Nature449(7164), 851–861 (2007).
   PubMed Web of Science ®Google Scholar
• Lander ES , LintonLM, BirrenBet al.: Initial sequencing and analysis of the human genome.Nature409(6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Kruglyak L : The road to genome-wide association studies.Nat. Rev. Genet.9(4), 314–318 (2008).
   PubMed Web of Science ®Google Scholar
• Chung CC , MagalhaesWC, Gonzalez-BosquetJ, ChanockSJ: Genome-wide association studies in cancer – current and future directions.Carcinogenesis31(1), 111–120 (2010).
   PubMed Web of Science ®Google Scholar
• Ioannidis JP , ThomasG, DalyMJ: Validating, augmenting and refining genome-wide association signals.Nat. Rev. Genet.10(5), 318–329 (2009).
   PubMed Web of Science ®Google Scholar
• Nilsson JA , ClevelandJL: Myc pathways provoking cell suicide and cancer.Oncogene22(56), 9007–9021 (2003).
   PubMed Web of Science ®Google Scholar
• Knowles MA : Bladder cancer subtypes defined by genomic alterations.Scand. J. Urol. Nephrol. Suppl.218, 116–130 (2008).
   Google Scholar
• Ahmadiyeh N , PomerantzMM, GrisanzioCet al.: 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.Proc. Natl Acad. Sci. USA107(21), 9742–9746 (2010).
   PubMed Web of Science ®Google Scholar
• Wang M , WangM, ZhangWet al.: Common genetic variants on 8q24 contribute to susceptibility to bladder cancer in a Chinese population.Carcinogenesis30(6), 991–996 (2009).
   PubMed Web of Science ®Google Scholar
• Saeki N , GuJ, YoshidaT, WuX: Prostate stem cell antigen: a Jekyll and Hyde molecule?Clin. Cancer Res.16(14), 3533–3538 (2010).
   PubMed Web of Science ®Google Scholar
• Urist MJ , Di ComoCJ, LuMLet al.: Loss of p63 expression is associated with tumor progression in bladder cancer.Am. J. Pathol.161(4), 1199–1206 (2002).
   PubMed Web of Science ®Google Scholar
• Koga F , KawakamiS, FujiiYet al.: Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder.Clin. Cancer Res.9(15), 5501–5507 (2003).
   PubMed Web of Science ®Google Scholar
• Rafnar T , SulemP, StaceySNet al.: Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.Nat. Genet.41(2), 221–227 (2009).
   PubMed Web of Science ®Google Scholar
• Hernandez S , Lopez-KnowlesE, LloretaJet al.: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.J. Clin. Oncol.24(22), 3664–3671 (2006).
   PubMed Web of Science ®Google Scholar
• Park JH , WacholderS, GailMHet al.: Estimation of effect size distribution from genome-wide association studies and implications for future discoveries.Nat. Genet.42(7), 570–575 (2010).
   PubMed Web of Science ®Google Scholar
• Wu X , LinJ, GrossmanHBet al.: Projecting individualized probabilities of developing bladder cancer in white individuals.J. Clin. Oncol.25(31), 4974–4981 (2007).
   PubMed Web of Science ®Google Scholar
• Via M , GignouxC, BurchardEG: The 1000 Genomes Project: new opportunities for research and social challenges.Genome Med.2(1), 3 (2010).
   PubMedGoogle Scholar
• Hirschhorn JN : Genome-wide association studies – illuminating biologic pathways.N. Engl. J. Med.360(17), 1699–1701 (2009).
   PubMed Web of Science ®Google Scholar
• Andrew AS , GuiJ, SandersonACet al.: Bladder cancer SNP panel predicts susceptibility and survival.Hum. Genet.125(5–6), 527–539 (2009).
   PubMed Web of Science ®Google Scholar
• Castillejo A , RothmanN, Murta-NascimentoCet al.: TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.Int. J. Cancer124(3), 608–613 (2009).
   PubMed Web of Science ®Google Scholar
• Wendt MK , AllingtonTM, SchiemannWP: Mechanisms of the epithelial–mesenchymal transition by TGF-β.Future Oncol.5(8), 1145–1168 (2009).
   PubMed Web of Science ®Google Scholar
• Marsh HP , HaldarNA, BunceMet al.: Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation.Br. J. Cancer89(6), 1096–1101 (2003).
   PubMed Web of Science ®Google Scholar
• Sakano S , KumarR, LarssonPet al.: A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder.BJU Int.97(4), 847–851 (2006).
   PubMed Web of Science ®Google Scholar
• Gu J , GrossmanHB, DinneyCP, WuX: The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence.Pharmacogenomics6(6), 575–584 (2005).
   PubMed Web of Science ®Google Scholar
• Leibovici D , GrossmanHB, DinneyCPet al.: Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival.J. Clin. Oncol.23(24), 5746–5756 (2005).
   PubMed Web of Science ®Google Scholar
• Ahirwar D , KesarwaniP, ManchandaPK, MandhaniA, MittalRD: Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette–Guerin immunotherapy in bladder cancer.Cancer Genet. Cytogenet.184(1), 1–8 (2008).
   PubMedGoogle Scholar
• Gu J , ZhaoH, DinneyCPet al.: Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.Clin. Cancer Res.11(4), 1408–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Sakano S , WadaT, MatsumotoHet al.: Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.Br. J. Cancer95(5), 561–570 (2006).
   PubMed Web of Science ®Google Scholar
• Sanyal S , de VerdierPJ, SteineckGet al.: Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms.Acta Oncol.46(1), 31–41 (2007).
   PubMed Web of Science ®Google Scholar
• Sanyal S , RykC, de VerdierPJet al.: Polymorphisms in NQO1 and the clinical course of urinary bladder neoplasms.Scand. J. Urol. Nephrol.41(3), 182–190 (2007).
   PubMed Web of Science ®Google Scholar
• Shinohara A , SakanoS, HinodaYet al.: Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.Cancer Sci.100(12), 2376–2382 (2009).
   PubMed Web of Science ®Google Scholar
• Tsuchiya N , InoueT, NaritaSet al.: Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.J. Urol.180(6), 2389–2395 (2008).
   PubMed Web of Science ®Google Scholar
• Yokomizo A , YamamotoK, KinukawaN, TsunodaT, KogaH, NaitoS: Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.Int. J. Urol.14(6), 500–504 (2007).
   PubMed Web of Science ®Google Scholar
• Rabik CA , DolanME: Molecular mechanisms of resistance and toxicity associated with platinating agents.Cancer Treat. Rev.33(1), 9–23 (2007).
   PubMed Web of Science ®Google Scholar
• Kang S , JuW, KimJWet al.: Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.Exp. Mol. Med.38(3), 320–324 (2006).
   PubMed Web of Science ®Google Scholar
• Pare L , MarcuelloE, AltesAet al.: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Br. J. Cancer99(7), 1050–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Suk R , GurubhagavatulaS, ParkSet al.: Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.Clin. Cancer Res.11(4), 1534–1538 (2005).
   PubMed Web of Science ®Google Scholar
• Sun X , LiF, SunNet al.: Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.Lung Cancer65(2), 230–236 (2009).
   PubMed Web of Science ®Google Scholar
• Wang M , WangM, YuanLet al.: A novel XPF-357A>C polymorphism predicts risk and recurrence of bladder cancer.Oncogene29(13), 1920–1928 (2010).
   PubMed Web of Science ®Google Scholar
• Rha SY , JeungHC, ChoiYHet al.: An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.Oncologist12(6), 622–630 (2007).
   PubMed Web of Science ®Google Scholar
• Soo RA , WangLZ, NgSSet al.: Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Lung Cancer63(1), 121–127 (2009).
   PubMed Web of Science ®Google Scholar
• Sugiyama E , KaniwaN, KimSRet al.: Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.J. Clin. Oncol.25(1), 32–42 (2007).
   PubMed Web of Science ®Google Scholar
• Tibaldi C , GiovannettiE, VasileEet al.: Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.Clin. Cancer Res.14(6), 1797–1803 (2008).
   PubMed Web of Science ®Google Scholar
• Wong A , SooRA, YongWP, InnocentiF: Clinical pharmacology and pharmacogenetics of gemcitabine.Drug Metab. Rev.41(2), 77–88 (2009).
   PubMed Web of Science ®Google Scholar
• Azzato EM , PharoahPD, HarringtonPet al.: A genome-wide association study of prognosis in breast cancer.Cancer Epidemiol. Biomarkers Prev.19(4), 1140–1143 (2010).
   PubMed Web of Science ®Google Scholar
• Daly AK : Genome-wide association studies in pharmacogenomics.Nat. Rev. Genet.11(4), 241–246 (2010).
   PubMed Web of Science ®Google Scholar
• Barrett JC , HansoulS, NicolaeDLet al.: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease.Nat. Genet.40(8), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Zeggini E , ScottLJ, SaxenaRet al.: Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for Type 2 diabetes.Nat. Genet.40(5), 638–645 (2008).
   PubMed Web of Science ®Google Scholar
• Kim EJ , JeongP, QuanCet al.: Genotypes of TNF-α, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer.Urology65(1), 70–75 (2005).
   PubMed Web of Science ®Google Scholar
• Mittal RD , SinghR, ManchandaPKet al.: XRCC1 codon 399 mutant allele: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.Cancer Biol. Ther.7(5), 645–650 (2008).
   PubMed Web of Science ®Google Scholar
• Gangwar R , MandhaniA, MittalRD: XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy.J. Cancer Res. Clin. Oncol.136(5), 779–786 (2010).
   PubMed Web of Science ®Google Scholar
• Horikawa Y , NadaokaJ, SaitoMet al.: Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.Oncol. Rep.20(1), 49–55 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao H , LiangD, GrossmanHB, WuX: Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer.Urology66(4), 769–774 (2005).
   PubMed Web of Science ®Google Scholar
• Lin J , DinneyCP, GrossmanHBet al.: E-cadherin promoter polymorphism (C-160A) and risk of recurrence in patients with superficial bladder cancer.Clin. Genet.70(3), 240–245 (2006).
   PubMed Web of Science ®Google Scholar
• Nadaoka J , HorikawaY, SaitoMet al.: Prognostic significance of HIF-1 a polymorphisms in transitional cell carcinoma of the bladder.Int. J. Cancer122(6), 1297–1302 (2008).
   PubMed Web of Science ®Google Scholar
• Sakano S , BerggrenP, KumarRet al.: Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene.Int. J. Cancer104(1), 98–103 (2003).
   PubMed Web of Science ®Google Scholar
• Riemann K , StruweH, EisenhardtA, ObermaierB, SchmidKW, SiffertW: Characterization of intron-1 haplotypes of the G protein β 4 subunit gene–association with survival and progression in patients with urothelial bladder carcinoma.Pharmacogenet. Genomics18(11), 999–1008 (2008).
   PubMed Web of Science ®Google Scholar
• Mason RA , MorlockEV, KaragasMRet al.: EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.Carcinogenesis30(7), 1155–1160 (2009).
   PubMed Web of Science ®Google Scholar
• Basturk B , YavascaogluI, OralB, GoralG, OktayB: Cytokine gene polymorphisms can alter the effect of Bacillus Calmette–Guerin (BCG) immunotherapy.Cytokine35(1–2), 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Ahirwar DK , AgrahariA, MandhaniA, MittalRD: Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy.Biomarkers14(4), 213–218 (2009).
   PubMed Web of Science ®Google Scholar
• Ahirwar DK , MandhaniA, DharaskarA, KesarwaniP, MittalRD: Association of tumour necrosis factor-α gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette–Guerin immunotherapy.BJU Int.104(6), 867–873 (2009).
   PubMed Web of Science ®Google Scholar
• Gangwar R , AhirwarD, MandhaniA, MittalRD: Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population?Mutat. Res.680(1–2), 56–63 (2009).
   PubMed Web of Science ®Google Scholar
• Gangawar R , AhirwarD, MandhaniA, MittalRD: Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.Med. Oncol.27(2), 159–166 (2010).
   PubMed Web of Science ®Google Scholar
• Gangwar R , MandhaniA, MittalRD: Caspase 9 and caspase 8 gene polymorphisms and susceptibility to bladder cancer in north Indian population.Ann. Surg. Oncol.16(7), 2028–2034 (2009).
   PubMed Web of Science ®Google Scholar
• Gangwar R , MittalRD: Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in north Indian population.DNA Cell Biol.29(7), 349–356 (2010).
   PubMed Web of Science ®Google Scholar
• Decobert M , LarueH, BergeronAet al.: Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette–Guerin immunotherapy for superficial bladder cancer.J. Urol.175(4), 1506–1511 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• IKCnet www.ikcnet.nl/page.php?id=2945&nav_id=114
   Google Scholar
• Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA: A catalog of published genome-wide association studies. www.genome.gov/gwastudies (Accessed on 23 June 2010)
   Google Scholar
• den Dunnen JT, Antonarakis SE. Hum. Mutat. 15, 7–12 (2000) www.hgvs.org/mutnomen/
   Google Scholar